Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Operating Margin: 2016-2025

Historic Operating Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 11,045.88%.

  • Rocket Pharmaceuticals' Operating Margin fell 369383.00% to 11,045.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,245.80%, marking a year-over-year decrease of 129430.00%. This contributed to the annual value of 14,485.95% for FY2024, which is 63747.00% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Operating Margin stood at 11,045.88%, which was down 26.57% from 15,042.07% recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Operating Margin registered a high of 15,650.11% during Q2 2024, and its lowest value of 2,268.48% during Q1 2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Operating Margin value was 13,950.75% (recorded in 2023), while the average stood at 13,915.80%.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Operating Margin spiked by 1,224,585bps in 2021, and later tumbled by 369,383bps in 2025.
  • Rocket Pharmaceuticals' Operating Margin (Quarterly) stood at 9,575.16% in 2021, then skyrocketed by 521,756bps to 14,792.72% in 2022, then slumped by 132,910bps to 13,463.62% in 2023, then tumbled by 20,907bps to 13,254.55% in 2024, then crashed by 369,383bps to 11,045.88% in 2025.
  • Its last three reported values are 11,045.88% in Q3 2025, 15,042.07% for Q2 2025, and 13,641.53% during Q1 2025.